NCT00697515View on ClinicalTrials.gov

Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

PHASE3CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

July 18, 2008

Primary Completion Date

December 20, 2008

Study Completion Date

December 20, 2008

Conditions
ADHD
Interventions
DRUG

LDX

oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting

DRUG

Placebo

Placebo administered once-daily for one week during the adult workplace environment setting

Trial Locations (5)

66212

Vince & Associates Clinical Research, Overland Park

72205

Clinical Study Centers, LLC, Little Rock

77007

Bayou City Research, LTD, Houston

89128

Center for Psychiatry & Behavioral Medicine, Inc, Las Vegas

92612

University of CA, Irvine Child Development Center, Irvine

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT00697515 - Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter